Biomarkers of Alzheimer's Disease Among Mexican Americans
Document Type
Journal Article
Keywords
Alzheimer's disease, biomarkers, Mexican American, neuropsychologyacid phosphatase prostate isoenzyme, alpha 1 antitrypsin, angiopoietin 2, beta 2 microglobulin, biological marker, C reactive protein, carcinoembryonic antigen, CD40 antigen, epidermal growth factor, fatty acid binding protein, glucagon like peptide 1, glutathione transferase, immunoglobulin M, insulin, interleukin 18, interleukin 8, macrophage derived chemokine, macrophage inflammatory protein 1alpha, migration inhibition factor, myoglobin, pancreas polypeptide, peptide YY, protein S100B, somatomedin, tenascin, thyrotropin, thyroxine binding globulin, tumor necrosis factor receptor 2, vascular cell adhesion molecule 1, aged, Alzheimer disease, area under the curve, article, clinical article, Clinical Dementia Rating, controlled study, DNA extraction, female, gene frequency, Hispanic, human, insulin blood level, male, mini mental state examination, priority journal, protein blood level, protein expression, random forest, receiver operating characteristic, sensitivity and specificity, Aged, Aged, 80 and over, Alzheimer Disease, Antigens, CD40, Biological Markers, Female, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Humans, Insulin, Male, Mental Status Schedule, Mexican Americans, Middle Aged, Pancreatic Polypeptide, Sensitivity and Specificity, Somatomedins
Publisher
IOS Press
Faculty
Faculty of Health, Engineering and Science
School
School of Medical Sciences
RAS ID
14937
Abstract
Background: Mexican Americans are the fastest aging segment of the U.S. population, yet little scientific literature exists regarding the Alzheimer's disease (AD) among this segment of the population. The extant literature suggests that biomarkers of AD will vary according to race/ethnicity though no prior work has explicitly studied this possibility. The aim of this study was to create a serum-based biomarker profile of AD among Mexican American. Methods: Data were analyzed from 363 Mexican American participants (49 AD and 314 normal controls) enrolled in the Texas Alzheimer's Research & Care Consortium (TARCC). Non-fasting serum samples were analyzed using a luminex-based multi-plex platform. A biomarker profile was generated using random forest analyses. Results: The biomarker profile of AD among Mexican Americans was different from prior work from non-Hispanic populations with regards to the variable importance plots. In fact, many of the top markers were related to metabolic factors (e.g., FABP, GLP-1, CD40, pancreatic polypeptide, insulin-like-growth factor, and insulin). The biomarker profile was a significant classifier of AD status yielding an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.77, 0.92, and 0.64, respectively. Combining biomarkers with clinical variables yielded a better balance of sensitivity and specificity. Conclusion: The biomarker profile for AD among Mexican American cases is significantly different from that previously identified among non-Hispanic cases from many large-scale studies. This is the first study to explicitly examine and provide support for blood-based biomarkers of AD among Mexican Americans. Areas for future research are highlighted.
Comments
O' Bryant, S., Xiao, G., Edwards, M., Devous, M., Gupta, V. B., Martins, R. N., Zhang, F., & Barber, R. (2013). Biomarkers of Alzheimer's Disease Among Mexican Americans. Journal of Alzheimer's Disease, 34(4), 841-849. Available here